Roche Breast Cancer Drug 

It has been reported that a new Roche breast cancer drug has benefits of extending lives in a clinical trial

Patients with breast cancer, HER2 positive, were given Perjeta on in addition to other medicines and chemotherapy lived 15.7 months longer than those who took Herceptin and chemotherapy alone.

This result shows that it is important to combine medicines that fight tumor cells in a variety of ways.

These results are according to a study by Sandra Swain from the Washington Hospital Center told the European Society for Medical Oncology (ESMO) and presented in the annual congress in Madrid on Sunday.

Perjeta, the Roche Breast Cancer Drug

Perjeta, the Roche Breast Cancer Drug which was approved by regulators two years ago was tested on more than 800 women.

The study results a different way, the risk of dying was reduced by 32 percent for women who received the Perjeta regimen compared to those who got Herceptin and chemotherapy.

It is important to note that both Perjeta and Herceptin have side effects which include rashes; diarrhea, a potentially bad impact on the heart, even though it was indicated that using the two drugs did not worsen the situation.

The cost in the United States of Perjeta is approximately $5,900 monthly while Herceptin costs around $5,300. This is as per a Roche spokeswoman who also indicated that the prices in Europe are lower.

Important to know

It is vital to know that the Cancer Drug Perjeta use in combination with Herceptin and docetaxel chemotherapy is an approved treatment approach in the United States and the EU for patients with previously untreated HER2-positive mBC

Roche the Company

The company at the center of this drug is Roche. In 2013, the Roche Group, as mentioned on its website, employed over 85,000 people worldwide. They also indicate that the group invested 8.7 billion Swiss francs in Research and Development with global sales amounting to 46.8 billion Swiss francs. The group owns wholly Genentech, in the United States, and is the majority shareholder in Chugai Pharmaceutical, Japan.


Please take note that all the information provided on the pages of this website is purely  provided for reference only and the specific sources and links indicated therein should be further researched for details. Also note that for specific diagnosis and treatment, which would result in the prescription of the above drug, please consult your personal professional physician.